<DOC>
	<DOC>NCT00547521</DOC>
	<brief_summary>To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept</brief_summary>
	<brief_title>Phase IIIB Subcutaneous Abatacept Monotherapy Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Clinical diagnosis of Rheumatoid Arthritis Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog scale Discontinue all Biologics and Diseasemodifying antirheumatic drugs (DMARDS) except for methotrexate Received treatment with rituximab Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba columns), mycophenolate mofetil (CellceptÂ®), cyclosporine A or other calcineurin inhibitors, or DPenicillamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>